Parathyroid carcinoma: An overview

Advances in Anatomic Pathology

Volumn 12, Issue 2, 2005, Pages 53-61

  DeLellis, Ronald A ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

HRPT2; Hyperparathyroidism jaw tumor syndrome; MEN1; MEN2; Parathyroid carcinoma

Indexed keywords

BLOOD VESSEL; BONE DISEASE; CANCER INCIDENCE; CANCER INVASION; CANCER RECURRENCE; CANCER SURGERY; GENE; GENE MUTATION; HRPT2 GENE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPARATHYROIDISM JAW TUMOR SYNDROME; JAW TUMOR; KIDNEY DISEASE; METASTASIS; MITOSIS; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PRIORITY JOURNAL; REVIEW; SEX RATIO; SOFT TISSUE; SURGICAL APPROACH; THYROID GLAND;

CARCINOMA; EUROPE; FEMALE; HUMANS; HYPERPARATHYROIDISM; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PARATHYROID NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEINS; UNITED STATES;

EID: 17144379723     PISSN: 10724109     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pap.0000151319.42376.d4     Document Type: Review

References (82)

1. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000;343:1863-1874.
2. Gallagher SF, Denham DW, Murr MM. The impact of minimally invasive parathyroidectomy on the way endocrinologists treat primary hyperparathyroidism. Surgery. 2003;134:910-917.
3. Castleman B, Roth SI. Tumors of the Parathyroid Glands. Atlas of Tumor Pathology. 2nd series, fascicle 14. Washington, DC: Armed Forces Institute of Pathology; 1978.
4. rd series, fascicle 6. Washington, DC: Armed Forces Institute of Pathology; 1993.
5. Hundahl SA, Fleming ID, Fremgen AM, et al. Two hundred eighty-six cases of parathyroid carcinomas treated in the U.S. between 1985-1995. A National Cancer Data Base Report. The American College of Surgeons Commission and the American Cancer Society. Cancer. 1999;86:538-544.
6. Shane E. Clinical review 122. Parathyroid carcinoma. J Clin Endocrinol Metab. 2001;86:485-493.
7. Obara T, Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma. An update and review. World J Surg. 1991;15:738-744.
8. Favia G, Lumachi F, Polistina F, et al. Parathyroid carcinoma. World J Surg. 1998;22:1225-1230.
9. Kebebew E. Parathyroid carcinoma. Curr Treat Options Oncol. 2001:2:347-354.
10. Witteles RM, Straus FH, Lakshmana M, et al. Parathyroid carcinoma. In: Randolph G, ed. Surgery of the Thyroid and Parathyroid Glands. Philadelphia: Saunders; 2002:578-590.
11. Koea IB, Shaw JH. Parathyroid cancer: biology and management. Surg Oncol. 1999;8:155-165.
12. Rasmuson T, Damber L, Johansson L, et al. Increased incidence of parathyroid adenomas following X-ray treatment of benign disease in the cervical spine in adult patients. Clin Endocrinol (Oxf). 2002;57:731-734.
13. Miki H, Sumitomo M, Inoue H, et al. Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. Surgery. 1996;120:897-901.
14. Djema AI, Mahmoud MD, Collin P, et al. Tertiary hyperparathyroidism: parathyroid cancer with liver metastasis in a hemodialyzed patient. Nephrologia. 1998;19:121-123.
15. Jayawardene S, Owen WJ, Goldsmith DJ. Parathyroid carcinoma in a dialysis patient. Am J Kidney Dis. 2000;36:E26.
16. Kuji T, Kitamura H, Yasuda G, et al. Different pathological findings in each of four parathyroid glands in a long-standing hemodialysis patient. Clin Nephrol. 2000;54:413-417.
17. Srouji IA, Resouly A, Cree IA. Case of thymic parathyroid carcinoma in a haemodialysis patient: application of tumour chemosensitivity testing. J Laryngol Otol. 2004;118:162-164.
18. Tominaga Y, Numano M, Uchida K, et al. Lung metastasis from parathyroid carcinoma causing recurrent renal hyperparathyroidism in a hemodialysis patient: report of a case. Surg Today. 1995;25:984-986.
19. Boyle NH, Ogg CS, Hartley RB, et al. Parathyroid carcinoma secondary to prolonged hyperplasia in chronic renal failure and coeliac disease. Eur J Surg Oncol. 1999;25:100-103.
20. Takami H, Kameyama K, Nagakubo I. Parathyroid carcinoma in a patient receiving long term hemodialysis. Surgery. 1999;125:239-240. Letter.
21. Ireland JP, Fleming SJ, Levinson DA, et al. Parathyroid carcinoma associated with chronic renal failure and previous radiotherapy to the neck. J Clin Pathol. 1985;38:1114-1118.
22. Dinnen JS, Greenwood RH, Jones JH, et al. Parathyroid carcinoma in familial hyperparathyroidism. J Clin Pathol. 1977;30:966-975.
23. Marx SJ, Simmonds WF, Agarwal SK, et al. Hereditary hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res. 2002;17 (suppl 2):N37-N43.
24. Brandi ML, Falchetti A. Genetics of primary hyperparathyroidism. Urol Int. 2004;72 (suppl):11-16.
25. Marx S, Spiegel AM, Skarulis MC, et al. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann intern Med. 1998;129:484-494.
26. Agarwal SK, Lee Burns A, Sukhodolets KE, et al. Molecular pathology of the MEN1 gene. Ann NY Acad Sci. 2004;1014:189-198.
27. Dionisi S, Minisola S, Pepe J, et al. Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type I: presentation as hypercalcemic crisis. Mayo Clin Proc. 2002;77:866-869.
28. DeLellis RA. Multiple endocrine neoplasia syndromes revisited. Clinical, morphological and molecular features. Lab Invest. 1995;72:494-505.
29. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia typ 2. International RET Mutation Consortium Analysis. JAMA. 1996;276:1575-1579.
30. Jenkins PJ, Satta MA, Simmgen M, et al. Metastatic parathyroid carcinoma in the MEN2A syndrome. Clin Endocrinol. 1997;47:747-751.
31. Thakker RV. Diseases associated with the extracellular calcium receptor. Cell Calcium. 2004;35:275-282.
32. Chen JD, Morrison C, Zhang C, et al. Hyperparathyroidism-jaw tumor syndrome. J Intern Med. 2003;253:634-642.
33. Malette LE, Malini S, Rappaport MP, et al. Familial cystic parathyroid adenomatosis. Ann Intern Med. 1987;107:54-60.
34. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32:676-680.
35. Simonds WF, James-Newton O, Agarwal SK, et al. Familial isolated hyperthyroidism. Clinical and genetic characterizations of 36 kindreds. Medicine. 2002;81:1-26.
36. Simonds WF, Robbins CM, Agarwal SK, et al. Familial isolated hyperparathyroidism is rarely caused by germline mutations in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndromes. J Clin Endocrinol Metab. 2004;89:96-102.
37. Warner J, Epstein M, Sweet A, et al. Genetic testing in familial isolated hyperparathyroidism. J Med Genet. 2004;41:155-160.
38. Carling T, Szabo E, Bai M, et al. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab. 2000;85:2042-2047.
39. Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer. 1973;31:600-605.
40. Wang CA, Gaz RD. Natural history of parathyroid carcinoma. Diagnosis, treatment and results. Am J Surg. 1985;149:522-527.
41. Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol. 1993;17:820-829.
42. Sandelin K, Auer G, Bondeson L, et al. Prognostic factors in parathyroid cancer. World J Surg. 1992;16:724-731.
43. Reddick RL, Costa J, Marx SJ. Parathyroid hyperplasias and parathyromatosis. Lancet. 1977;1:549.
44. Stehman-Breen C, Muirhead N, Thorning DS, et al. Secondary hyperparathyroidism complicated by parathyromatosis. Am J Kidney Dis. 1996;28:502-507.
45. Snover DC, Foucar K. Mitotic activity in benign parathyroid diseases. Am J Clin Pathol. 1981;75:345-347.
46. San Juan J, Monteagudo C, Fraker D, et al. Significance of mitotic activity and other morphological parameters in parathyroid adenomas and their correlation with clinical behavior. Am J Clin Pathol. 1989;92:523. Abstract.
47. Nacamuli R, Rumore GJ, Clark G. Parathyroid carcinosarcoma: a previously unreported entity. Am Surg. 2002;68:900-903.
48. Erickson LA, Jin L, Papotti M, et al. Oxyphil parathyroid carcinomas. A clinicopathologic and immunohistochemical study of 10 cases. Am J Surg Pathol. 2002;26:344-349.
49. Levin KE, Chew KL, Ljung BM, et al. Deoxyribonucleic acid cytometry helps identify parathyroid carcinomas. J Clin Endocrinol Metab. 1988;67:779-784.
50. Guiter GE, DeLellis RA. Risk of recurrence or metastases in atypical parathyroid adenomas. Mod Pathol. 2002;15:115A. Abstract.
51. Erickson LA, Lloyd RV. Practical markers used in the diagnosis of endocrine tumors. Adv Anat Pathol. 2004;11:175-189.
52. Abbona GC, Papotti M, Gaspard G, et al. Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol. 1995;26;135-158.
53. Farnebo F, Auer G, Farnebo L-O. Evaluation of retinoblastoma and Ki67 as diagnostic markers in benign and malignant parathyroid disease. World J Surg. 1999;23:68-74.
54. Kameyama K, Takami H, Umemura S, et al. PCNA and Ki-67 as prognostic markers in human parathyroid carcinomas. Ann Surg Oncol. 2000;7:301-305.
55. Lloyd RV, Carney JH, Ferreiro JA, et al. Immunohistochemical analysis of the cell cycle associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinoma and adenomas. Endocr Pathol. 1995;6:279-287.
56. Naccaroto AG, Marocci C, Miccoli P, et al. Bcl-2, p53 and MIB-1 expression in normal and neoplastic parathyroid tissue. J Endocrinol Invest. 1998;21:136-141.
57. Vargas MP, Vargas HI, Kleiner DE, et al. The role of prognostic markers (MiB-1, RB, and Bcl-2) in the diagnosis of parathyroid tumors. Mod Palhol. 1997;10:12-17.
58. Kip1 protein. Am J Surg Pathol. 1999;23:288-295.
59. Vasef MA, Brynes RK, Sturm M, et al. Expression of cyclin D1 in parathyroid carcinomas, adenomas and hyperplasias. Mod Pathol. 1999;12:412-416.
60. Haven CJ, van Puijenbroek M, Karperien M, et al. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol. 2004;202:86-94.
61. Stojadinovic A, Hoos A, Nissan A, et al. Parathyroid neoplasms: clinical, histopathological and tissue microarray-based molecular analysis. Hum Pathol. 2003;34:54-64.
62. Cryns VK, Thor A, Xu HJ, et al. Loss of the retinoblastoma tumor suppressor gene in parathyroid carcinoma. N Engl J Med. 1994;330:757-761.
63. Obara T, Fujimoto Y, Kanaji Y, et al. Flow cytometric DNA analysis of parathyroid tumors. Implication of aneuploidy for pathologic and biologic classification. Cancer. 1999;66:1555-1562.
64. Harlow S, Roth SI, Bauer K, et al. Flow cytometric DNA analysis of normal and pathologic parathyroid glands. Mod Pathol. 1991;4:310-315.
65. Arnold A, Shattuck TM, Mallya SM, et al. Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res. 2002;17 (suppl 2):N30-N36.
66. Carling T. Molecular pathology of parathyroid tumors. Trends Endocrinol Metab. 2001;12:53-58.
67. Palanismy N, Imanishi Y, Rao PH, et al. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab. 1998;83:1766-1770.
68. Farnebo F, Kytola S, Teh BT, et al. Alternative genetic pathways in parathyroid tumorigenesis. J Clin Endocrinol Metab. 1999;84:3775-3780.
69. Agarwal SK, Schrock E, Kester MB, et al. Comparative genomic hybridization analysis of human parathyroid tumors. Cancer Genet Cytogenet. 1998;106:30-36.
70. Kytola S, Farnebo F, Obara T, et al. Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol. 2000;157:579-586.
71. Erickson LA, Jalal SM, Harwood A, et al. Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization. Am J Surg Pathol. 2004;28:578-584.
72. Valimaki S, Forsberg L, Farnebo LO, et al. Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas. Int J Oncol. 2002;21:727-735.
73. Pearce SH, Trump D, Wooding C, et al. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumors. Clin Endocrinol. 1996;45:195-200.
74. Cetani F, Pardi E, Vlacava P, et al. A reappraisal of the Rb1 gene abnormalities in the diagnoses of parathyroid carcinoma. Clin Endocrinol. 2004;60:99-106.
75. Shattuck TM, Kim TS, Costa J, et al. Mutational analysis of RB and BRCA2 as candidate tumor suppressor genes in parathyroid carcinoma. Clin Endocrinol. 2003;59:180-189.
76. Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumors. J Med Genet. 2003;40:657-663.
77. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germline mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349:1722-1729.
78. Weinstein LS, Simonds WF. HRPT2, a marker of parathyroid cancer. N Engl J Med. 2003;349:1691-1692.
79. Villablanca A, Farnebo F, Teh BT, et al. Genetic and clinical characterization of cystic parathyroid tumors. Clin Endocrinol. 2002;56:261-269.
80. Thompson SD, Prichard AJN. The management of parathyroid carcinoma. Curr Opin Otolaryngol Head Neck Surg. 2004;12:93-97.
81. Clayman GL, Gonzalez HE, El-Naggar A, et al. Parathyroid carcinoma; evaluation and interdisciplinary management. Cancer. 2004;100:900-905.
82. Shaha AR, Shah JP. Parathyroid carcinoma. A diagnostic and therapeutic challenge. Cancer. 1999;86:378-380.